Expression and significance of fgl2 prothrombinase in cardiac microvascular endothelial cells of rats with type 2 diabetes

  • Yanping Ding (丁艳萍)
  • Kun Liu (刘 坤)
  • Yan Wang (汪 艳)
  • Guanhua Su (苏冠华)
  • Heping Deng (邓荷萍)
  • Qiutang Zeng (曾秋棠)
  • Yuhua Liao (廖玉华)
  • Zhaohui Wang (王朝晖)Email author


Microthrombosis may be involved in the pathogenesis of cardiac microangiopathy due to diabetes. Recent studies have shown that fibrinogen-like protein 2 (fgl2) plays a pivotal role in microthrombosis in viral hepatitis, acute vascular xenograft rejection and cytokine-induced fetal loss syndrome. The current study was designed to examine the expression of fgl2 in microvascular endothelial cells and investigate the effects of microthrombi due to fgl2 on cardiac function and structure in rats with type 2 diabetes. Following induction of type 2 diabetes, 24 rats were observed dynamically. Fgl2 expression and related cardiac microthrombosis were examined. Local or circulating TNF-α was measured. Coronary flow (CF) per min was calculated as an index of cardiac microcirculation. Cardiac function and morphology were evaluated. It was found that Fgl2 was highly expressed in cardiac microvascular endothelial cells of rats with type 2 diabetes, which was promoted by local or circulating TNF-α. The Fgl2 expression was associated with cardiac hyaline microthrombosis. In parallel with the fgl2 expression, CF per min, cardiac diastolic or systolic function and cardiac morphology were aggravated to some extent. It was concluded that in rats with type 2 diabetes, microthrombosis due to fgl2 contributes to the impairment of cardiac diastolic or systolic function and morphological changes.

Key words

fibrinogen-like protein 2 type 2 diabetes ischemic heart disease microangiopathy tumor necrosis factor-α cardiac function 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Beckman JA, Greager MA, Libby P. Diabetes and atherosclerosis: Epidemiology, pathophysiology, and management. JAMA, 2002,287(19):2570–2581CrossRefPubMedGoogle Scholar
  2. 2.
    Yarom R, Zirkin H, Stammler G, et al. Human coronary microvessels in diabetes and ischaemia. Morphometric study of autopsy material. J Pathol, 1992,166(3):265–270CrossRefPubMedGoogle Scholar
  3. 3.
    Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med, 2000,342(24):1792–1801CrossRefPubMedGoogle Scholar
  4. 4.
    Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications, 2001,15(1):44–54CrossRefPubMedGoogle Scholar
  5. 5.
    Boeri D, Maiello M, Lorenzi M. Increased prevalence of microthromboses in retinal capillaries of diabetic individuals. Diabetes, 2001,50(6):1432–1439CrossRefPubMedGoogle Scholar
  6. 6.
    Levy GA, Liu M, Ding J, et al. Molecular and functional analysis of the human prothrombinase gene (HFGL2) and its role in viral hepatitis. Am J Pathol, 2000,156(4):1217–1225PubMedGoogle Scholar
  7. 7.
    Chan CW, Chan MW, Liu M, et al. Kinetic analysis of a unique direct prothrombinase, fgl2, and identification of a serine residue critical for the prothrombinase activity. J Immunol, 2002,168(10):5170–5177PubMedGoogle Scholar
  8. 8.
    Ding JW, Ning Q, Liu MF, et al. Fulminant hepatic failure in murine hepatitis virus strain 3 infection: Tissue-specific expression of a novel fgl2 prothrombinase. J Virol, 1997,71(12):9223–9230PubMedGoogle Scholar
  9. 9.
    Marsden PA, Ning Q, Fung LS, et al. The Fgl2/fibroleukin prothrombinase contributes to immunologically mediated thrombosis in experimental and human viral hepatitis. J Clin Invest, 2003,112(1):58–66PubMedGoogle Scholar
  10. 10.
    Ghanekar A, Mendicino M, Liu H, et al. Endothelial induction of fgl2 contributes to thrombosis during acute vascular xenograft rejection. J Immunol, 2004,172(9): 5693–5701PubMedGoogle Scholar
  11. 11.
    Mendicino M, Liu M, Ghanekar A, et al. Targeted deletion of Fgl-2/fibroleukin in the donor modulates immunologic response and acute vascular rejection in cardiac xenografts. Circulation, 2005,112(2):248–256CrossRefPubMedGoogle Scholar
  12. 12.
    Clark DA, Ding JW, Chaouat G, et al. The emerging role of immunoregulation of fibrinogen-related procoagulant Fgl2 in the success or spontaneous abortion of early pregnancy in mice and humans. Am J Reprod Immunol, 1999,42(1):37–43PubMedGoogle Scholar
  13. 13.
    Knackstedt MK, Zenclussen AC, Hertwig K, et al. Th1 cytokines and the prothrombinase fgl2 in stress-tri ggered and inflammatory abortion. Am J Reprod Immunol, 2003,49(4):210–220CrossRefPubMedGoogle Scholar
  14. 14.
    Clark DA, Foerster K, Fung L, et al. The fgl2 prothrombinase/fibroleukin gene is required for lipopolysaccharide-triggered abortions and for normal mouse reproduction. Mol Hum Reprod, 2004,10(2):99–108CrossRefPubMedGoogle Scholar
  15. 15.
    Luo J, Quan J, Tsai J, et al. Nongenetic mouse models of non-insulin-dependent diabetes mellitus. Metabolism, 1998,47(6):663–668CrossRefPubMedGoogle Scholar
  16. 16.
    Doolittle RF. The structure and evolution of vertebrate fibrinogen. Ann N Y Acad Sci, 1983,408:13–27CrossRefPubMedGoogle Scholar
  17. 17.
    Levy GA, Marsden P, Zhong R, et al. Strategies to prevent thrombosis in xenotransplants. Transplant Proc, 1998,30(5):2458–2460CrossRefPubMedGoogle Scholar
  18. 18.
    Ning Q, Brown D, Parodo J, et al. Ribavirin inhibits viral-induced macrophage production of TNF-α, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J Immunol, 1998,160(7):3487–3493PubMedGoogle Scholar
  19. 19.
    Clark DA, Chaouat G, Arck PC, et al. Cytokine-dependent abortion in CBA × DBA/2 mice is mediated by the procoagulant fgl2 prothrombinase [correction of prothombinase]. J Immunol, 1998,160(2): 545–549PubMedGoogle Scholar
  20. 20.
    Clark DA, Ding JW, Yu G, et al. Fgl2 prothrombinase expression in mouse trophoblast and decidua triggers abortion but may be countered by OX-2. Mol Hum Reprod, 2001,7(2):185–194CrossRefPubMedGoogle Scholar
  21. 21.
    Liu M, Mendicino M, Ning Q, et al. Cytokine-induced hepatic apoptosis is dependent on FGL2/fibroleukin: the role of Sp1/Sp3 and STAT1/PU.1 composite cis elements. J Immunol, 2006,176(11):7028–7038PubMedGoogle Scholar
  22. 22.
    Aldhahi W, Hamdy O. Adipokines, inflammation, and the endothelium in diabetes. Curr Diab Rep, 2003,3(4): 293–298CrossRefPubMedGoogle Scholar
  23. 23.
    Rader DJ. Inflammatory markers of coronary risk. N Eng J Med, 2000,343(16):1179–1182CrossRefGoogle Scholar
  24. 24.
    Yagihashi S, Wada R, Yamagishi S. Diabetic microangiopathy: pathology and current understanding of its pathogenesis. Verh Dtsch Ges Pathol, 2002,86:91–100PubMedGoogle Scholar
  25. 25.
    Rubler S, Dlugash J, Yuceoglu YZ, et al. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol, 1972,30(6):595–602CrossRefPubMedGoogle Scholar
  26. 26.
    Hamby RI, Zoneraich S, Sherman L. Diabetic cardiomyopathy. JAMA, 1974,229(13):1749–1754.CrossRefPubMedGoogle Scholar
  27. 27.
    Dhalla NS, Liu X, Panagia V, et al. Subcellular remodeling and heart dysfunction in chronic diabetes. Cardiovasc Res, 1998,40(2):239–247CrossRefPubMedGoogle Scholar

Copyright information

© Huazhong University of Science and Technology and Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  • Yanping Ding (丁艳萍)
    • 1
  • Kun Liu (刘 坤)
    • 1
  • Yan Wang (汪 艳)
    • 1
  • Guanhua Su (苏冠华)
    • 1
  • Heping Deng (邓荷萍)
    • 2
  • Qiutang Zeng (曾秋棠)
    • 1
  • Yuhua Liao (廖玉华)
    • 1
  • Zhaohui Wang (王朝晖)
    • 1
    Email author
  1. 1.Department of CardiologyHuazhong University of Science and TechnologyWuhanChina
  2. 2.Department of Ultrasonic Medicine, Union Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina

Personalised recommendations